Arcadia Investment Management Corp MI Buys Shares of 3,584 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Arcadia Investment Management Corp MI bought a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 3,584 shares of the medical device company’s stock, valued at approximately $129,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Brooklyn Investment Group bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at approximately $28,000. Assetmark Inc. acquired a new stake in Tandem Diabetes Care during the 3rd quarter worth approximately $29,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Tandem Diabetes Care by 4.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,664 shares of the medical device company’s stock worth $664,000 after buying an additional 704 shares during the period. Hanseatic Management Services Inc. boosted its position in Tandem Diabetes Care by 5.4% during the 3rd quarter. Hanseatic Management Services Inc. now owns 13,941 shares of the medical device company’s stock worth $591,000 after buying an additional 710 shares during the period. Finally, Coldstream Capital Management Inc. boosted its position in Tandem Diabetes Care by 14.0% during the 3rd quarter. Coldstream Capital Management Inc. now owns 6,212 shares of the medical device company’s stock worth $263,000 after buying an additional 762 shares during the period.

Analyst Ratings Changes

Several research firms recently commented on TNDM. Canaccord Genuity Group cut their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Barclays boosted their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Citigroup dropped their price target on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target on the stock. Finally, Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target on the stock in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.81.

Tandem Diabetes Care Trading Up 1.3 %

NASDAQ:TNDM opened at $32.12 on Friday. The company has a fifty day moving average of $35.51 and a 200-day moving average of $36.82. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a twelve month low of $22.03 and a twelve month high of $53.69.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.